Watch NERV. Know when insiders buy.
One email the day a filing lands. Free.
NERV
Minerva Neurosciences, Inc.
3.49
−0.19 −5.29%
USD · close Sep 23
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
8
FLAG · shorts 8
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $166.6MP/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$394.3M −3611.7%NET CASH $15.3M52W 2.10 – 8.07SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$10.6M | $17.5M | — | -0.14 | −$13.3M | — | — | Aug 7 |
| Q1 2026 · Mar 31 | — | — | — | −$16.7M | −$125.4M | — | -2.86 | −$5.4M | — | — | Aug 7 |
| Q4 2025 · Dec 31derived | — | — | — | −$5M | −$283.7M | — | -33.38 | −$4.5M | — | — | Mar 11 |
| Q3 2025 · Sep 30 | — | — | — | −$2.8M | −$2.7M | −112.2% | -0.36 | −$2.9M | — | — | Nov 5 |
| Q2 2025 · Jun 30 | — | — | — | −$3.4M | −$3.3M | — | -0.43 | −$2M | — | — | Aug 7 |
| Q1 2025 · Mar 31 | — | — | — | −$3.9M | −$3.8M | — | -0.50 | −$4.1M | — | — | Aug 7 |
| Q4 2024 · Dec 31derived | — | — | — | −$4.5M | −$4.3M | — | -0.56 | −$5.2M | — | — | Mar 11 |
| Q3 2024 · Sep 30 | — | — | — | −$4.4M | $22.5M | — | 2.97 | −$4.4M | — | — | Nov 5 |
| Q2 2024 · Jun 30 | — | — | — | −$6.3M | −$8.2M | — | -1.09 | −$3.9M | — | — | Nov 5 |
| Q1 2024 · Mar 31 | — | — | — | −$6.7M | −$8.6M | — | -1.13 | −$6.1M | — | — | Nov 5 |
| Q4 2023 · Dec 31derived | — | — | — | −$7.2M | −$9M | — | -1.20 | −$6M | — | — | Feb 25 |
| Q3 2023 · Sep 30 | — | — | — | −$6.1M | −$7.8M | — | -1.03 | −$4.8M | — | — | Nov 5 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$15.1M | −$293.4M | — | -34.67 | −$13.5M | — | — | — | — |
| FY2024 · to Dec 31 | $0 | — | −$21.8M | $1.4M | — | 0.19 | −$19.6M | — | — | — | — |
| FY2023 · to Dec 31 | $0 | — | −$23.1M | −$30M | — | -4.61 | −$14.8M | — | — | — | — |
| FY2022 · to Dec 31 | $0 | — | −$25.2M | −$32.1M | — | -6.01 | −$24.6M | $16K | −$24.7M | — | — |
| FY2021 · to Dec 31 | $0 | — | −$45.4M | −$49.9M | — | -9.35 | −$24.6M | — | — | — | — |
| FY2020 · to Dec 31 | $41.2M | — | $1.8M | $1.9M | 4.7% | 0.05 | −$33.8M | — | — | — | — |
Every number comes from Minerva Neurosciences, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.